Free account + included starter software — credential review typically takes 1–2 business days. See how it works
NDC 62756-0457-88

CARBIDOPA AND LEVODOPA 50 mg/1, 200 mg/1 TABLET, EXTENDED RELEASE

Available — 2-Day Shipping
NDC
62756-0457-88
Generic Name
CARBIDOPA AND LEVODOPA
Brand Name
CARBIDOPA AND LEVODOPA
Strength
50 mg/1, 200 mg/1
Dosage Form
TABLET, EXTENDED RELEASE
Route
ORAL
Package Size
Labeler
Sun Pharmaceutical Industries, Inc.

FDA Drug Information

Indications & Usage

INDICATIONS AND USAGE Carbidopa and levodopa extended-release tablets are indicated in the treatment of Parkinson's disease, post-encephalitic parkinsonism, and symptomatic parkinsonism that may follow carbon monoxide intoxication or manganese intoxication.

Important Warnings

WARNINGS When patients are receiving levodopa without a decarboxylase inhibitor, levodopa must be discontinued at least twelve hours before carbidopa and levodopa extended-release tablets are started. In order to reduce adverse reactions, it is necessary to individualize therapy. See DOSAGE AND ADMINISTRATION section before initiating therapy. Carbidopa and levodopa extended-release tablets should…

Source: FDA. For professional use only. Not a substitute for prescribing information.

Order NDC 62756-0457-88 at Wholesale

Create a free Premier Pharma account to unlock live wholesale pricing and place orders with same-day fulfillment and full DSCSA T2 documentation (TI + TS).